Reata Pharmaceuticals (RETA) Earning Somewhat Positive Press Coverage, Accern Reports
Media headlines about Reata Pharmaceuticals (NASDAQ:RETA) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.6504295266762 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Reata Pharmaceuticals Inc (RETA) Major Shareholder James W. Traweek, Jr. Purchases 17,000 Shares (americanbankingnews.com)
- R Kent Mcgaughy, Jr. Buys 17,000 Shares of Reata Pharmaceuticals Inc (RETA) Stock (americanbankingnews.com)
- Reata Pharmaceuticals Inc (RETA) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- James W. Traweek, Jr. Purchases 12,000 Shares of Reata Pharmaceuticals Inc (RETA) Stock (americanbankingnews.com)
- Insider Buying: Reata Pharmaceuticals Inc (RETA) Director Purchases 15,000 Shares of Stock (americanbankingnews.com)
Several brokerages have issued reports on RETA. Cowen reissued a “buy” rating on shares of Reata Pharmaceuticals in a research note on Thursday, December 14th. Leerink Swann began coverage on shares of Reata Pharmaceuticals in a research note on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 price objective on the stock. Jefferies Group reissued a “buy” rating and issued a $44.00 price objective on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. ValuEngine cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, BidaskClub cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $54.71.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.11). The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $12.54 million. The business’s revenue was up .0% compared to the same quarter last year. equities research analysts anticipate that Reata Pharmaceuticals will post -1.91 earnings per share for the current fiscal year.
In related news, Director Cpmg Inc purchased 200,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were acquired at an average cost of $24.79 per share, with a total value of $4,958,000.00. Following the purchase, the director now directly owns 113 shares in the company, valued at approximately $2,801.27. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder James W. Traweek, Jr. purchased 17,000 shares of the stock in a transaction dated Saturday, December 29th. The shares were bought at an average cost of $28.47 per share, for a total transaction of $483,990.00. Following the completion of the purchase, the insider now owns 35 shares in the company, valued at $996.45. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 413,813 shares of company stock worth $10,453,354. Corporate insiders own 44.00% of the company’s stock.
WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/01/02/reata-pharmaceuticals-reta-earning-somewhat-positive-press-coverage-accern-reports.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.